Journal of Diabetes Research / 2015 / Article / Tab 2

Review Article

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

Table 2

Main features of DPP-4 inhibitors versus other (non-incretin-based) oral antidiabetic drugs, Table 1.

ClassMechanisms of actionEffects/advantagesAdverse reactionsΔHbA1c (%)

DPP-4 inhibitorsInhibit metabolism by DPP-4 enzyme
Increase the endogenous bioactive form of GLP-1
Reduce blood glucose levels and the postprandial glucose excursion
Have no effects on body weight
Have possible effects on pancreatic β cells mass
Perform oral administration
Abdominal pain
Nausea and vomiting
Diarrhoea
Nasopharyngitis
Respiratory infections
Headache
0.5–1.0

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.